Pub Date : 2025-03-08DOI: 10.1016/j.jaad.2025.01.102
Melissa C Leeolou, Justin L Jia, Kavita Y Sarin
{"title":"Navigating patient access to treatment: a focus on pharmaceutical drug samples.","authors":"Melissa C Leeolou, Justin L Jia, Kavita Y Sarin","doi":"10.1016/j.jaad.2025.01.102","DOIUrl":"https://doi.org/10.1016/j.jaad.2025.01.102","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143597207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-08DOI: 10.1016/j.jaad.2025.03.010
Christina S Oh, Nnaemeka Anyanwu, Michael G Buontempo, Deesha Desai, Ambika Nohria, Jerry Shapiro, Kristen Lo Sicco
{"title":"Evaluating Patient's Ability to Detect Changes in Hair Density Using Standardized Global Scalp Photography: A Cross-Sectional Study.","authors":"Christina S Oh, Nnaemeka Anyanwu, Michael G Buontempo, Deesha Desai, Ambika Nohria, Jerry Shapiro, Kristen Lo Sicco","doi":"10.1016/j.jaad.2025.03.010","DOIUrl":"https://doi.org/10.1016/j.jaad.2025.03.010","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143597206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-07DOI: 10.1016/j.jaad.2025.01.089
Kenneth B Gordon, Matthias Augustin, Jonathan Barker, Yayoi Tada, Mark G Lebwohl, Ming Tang, Patrick Hofmann, Christian Thoma, Alice B Gottlieb
Background: Generalized pustular psoriasis (GPP) is a chronic inflammatory disease with an unpredictable disease course. Long-term treatment goals include sustained resolution of skin symptoms, prevention of new flares, and improvement in quality of life (QoL).
Objective: To compare the effect of the interleukin-36 receptor monoclonal antibody spesolimab 600 mg subcutaneous (SC) loading dose (LD) followed by 300 mg SC every 4 weeks (q4w) versus placebo on skin symptoms and QoL burden in patients with GPP.
Methods: A post hoc analysis of the EFFISAYIL 2 trial (NCT04399837) was conducted to assess the proportion of patients with sustained improvement of skin symptoms (GPP Physician Global Assessment total score, 0 or 1) and QoL burden (Dermatology Life Quality Index score, 0 or 1) at all visits up to week 48.
Results: Among the patients who received spesolimab 600 mg SC LD followed by 300 mg SC q4w, 63.3% had sustained improvement of skin symptoms (vs 29.0%; placebo), and 24.1% had sustained improvement of QoL burden (vs 3.2%; placebo).
Limitations: Retrospective, descriptive, post hoc analysis.
Conclusion: Spesolimab 600 mg SC LD followed by 300 mg SC q4w provides sustained improvement of skin symptoms and QoL burden in a substantially higher proportion of patients with GPP versus placebo.
{"title":"Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL 2 study.","authors":"Kenneth B Gordon, Matthias Augustin, Jonathan Barker, Yayoi Tada, Mark G Lebwohl, Ming Tang, Patrick Hofmann, Christian Thoma, Alice B Gottlieb","doi":"10.1016/j.jaad.2025.01.089","DOIUrl":"10.1016/j.jaad.2025.01.089","url":null,"abstract":"<p><strong>Background: </strong>Generalized pustular psoriasis (GPP) is a chronic inflammatory disease with an unpredictable disease course. Long-term treatment goals include sustained resolution of skin symptoms, prevention of new flares, and improvement in quality of life (QoL).</p><p><strong>Objective: </strong>To compare the effect of the interleukin-36 receptor monoclonal antibody spesolimab 600 mg subcutaneous (SC) loading dose (LD) followed by 300 mg SC every 4 weeks (q4w) versus placebo on skin symptoms and QoL burden in patients with GPP.</p><p><strong>Methods: </strong>A post hoc analysis of the EFFISAYIL 2 trial (NCT04399837) was conducted to assess the proportion of patients with sustained improvement of skin symptoms (GPP Physician Global Assessment total score, 0 or 1) and QoL burden (Dermatology Life Quality Index score, 0 or 1) at all visits up to week 48.</p><p><strong>Results: </strong>Among the patients who received spesolimab 600 mg SC LD followed by 300 mg SC q4w, 63.3% had sustained improvement of skin symptoms (vs 29.0%; placebo), and 24.1% had sustained improvement of QoL burden (vs 3.2%; placebo).</p><p><strong>Limitations: </strong>Retrospective, descriptive, post hoc analysis.</p><p><strong>Conclusion: </strong>Spesolimab 600 mg SC LD followed by 300 mg SC q4w provides sustained improvement of skin symptoms and QoL burden in a substantially higher proportion of patients with GPP versus placebo.</p>","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-07DOI: 10.1016/j.jaad.2025.03.002
Dirk M Elston
{"title":"Letter from the editor: Improving outcomes for patients with central centrifugal cicatricial alopecia (CCCA).","authors":"Dirk M Elston","doi":"10.1016/j.jaad.2025.03.002","DOIUrl":"https://doi.org/10.1016/j.jaad.2025.03.002","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-06DOI: 10.1016/j.jaad.2024.10.131
Andrea Quartey, Jules B Lipoff
{"title":"Is TikTok the new Google? Content and Source Analysis of Google and TikTok as Search Engines for Dermatologic Content in 2024.","authors":"Andrea Quartey, Jules B Lipoff","doi":"10.1016/j.jaad.2024.10.131","DOIUrl":"https://doi.org/10.1016/j.jaad.2024.10.131","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-06DOI: 10.1016/j.jaad.2025.03.001
Dirk M Elston
{"title":"Letter from the editor: Desmoplastic melanoma behaves differently from other melanomas-American Joint Committee on Cancer staging should differ.","authors":"Dirk M Elston","doi":"10.1016/j.jaad.2025.03.001","DOIUrl":"10.1016/j.jaad.2025.03.001","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-05DOI: 10.1016/j.jaad.2025.02.086
David Pariser, Dee Anna Glaser, James Del Rosso, Neal Bhatia, Deirdre Hooper, Mark S Nestor, Stacy Smith, Joel Schlessinger, Adelaide Hebert, Patricia S Walker
Background: Current treatments for primary axillary hyperhidrosis are insufficient for some patients. Sofpironium topical gel is a retrometabolically-designed topical anticholinergic with rapid metabolism, which is associated with reduced side effects and targeted efficacy.
Objective: To assess efficacy and safety of sofpironium topical gel for primary axillary hyperhidrosis.
Methods: Cardigan I and Cardigan II were double-blind, randomized, controlled pivotal phase 3 studies of sofpironium topical gel, 12.45%, versus vehicle gel (1:1 randomization) for daily application to the axillae for 6 weeks.
Results: The combined Phase 3 studies included 353 subjects in the treatment groups and 348 subjects in the control groups. For the co-primary endpoint of ≥2-point improvement from baseline to end of treatment on Hyperhidrosis Disease Severity Measure-Axillary-7, pooled analyses showed significantly better results for treatment versus control (p<0.0001). For the pooled co-primary endpoint of gravimetric sweat production at treatment end, the treatment group had greater reduction in sweat production (p=0.0002). Secondary endpoints also showed a statistically significant benefit for sofpironium topical gel versus control. Treatment was well-tolerated.
Limitations: Short treatment and follow-up periods.
Conclusion: Sofpironium topical gel, 12.45%, applied topically once daily before bedtime is effective and well-tolerated for treatment of primary axillary hyperhidrosis in patients ≥9 years old.
{"title":"Sofpironium topical gel, 12.45%, for the treatment of axillary hyperhidrosis: pooled efficacy and safety results from 2 phase 3 randomized, controlled, double-blind studies.","authors":"David Pariser, Dee Anna Glaser, James Del Rosso, Neal Bhatia, Deirdre Hooper, Mark S Nestor, Stacy Smith, Joel Schlessinger, Adelaide Hebert, Patricia S Walker","doi":"10.1016/j.jaad.2025.02.086","DOIUrl":"https://doi.org/10.1016/j.jaad.2025.02.086","url":null,"abstract":"<p><strong>Background: </strong>Current treatments for primary axillary hyperhidrosis are insufficient for some patients. Sofpironium topical gel is a retrometabolically-designed topical anticholinergic with rapid metabolism, which is associated with reduced side effects and targeted efficacy.</p><p><strong>Objective: </strong>To assess efficacy and safety of sofpironium topical gel for primary axillary hyperhidrosis.</p><p><strong>Methods: </strong>Cardigan I and Cardigan II were double-blind, randomized, controlled pivotal phase 3 studies of sofpironium topical gel, 12.45%, versus vehicle gel (1:1 randomization) for daily application to the axillae for 6 weeks.</p><p><strong>Results: </strong>The combined Phase 3 studies included 353 subjects in the treatment groups and 348 subjects in the control groups. For the co-primary endpoint of ≥2-point improvement from baseline to end of treatment on Hyperhidrosis Disease Severity Measure-Axillary-7, pooled analyses showed significantly better results for treatment versus control (p<0.0001). For the pooled co-primary endpoint of gravimetric sweat production at treatment end, the treatment group had greater reduction in sweat production (p=0.0002). Secondary endpoints also showed a statistically significant benefit for sofpironium topical gel versus control. Treatment was well-tolerated.</p><p><strong>Limitations: </strong>Short treatment and follow-up periods.</p><p><strong>Conclusion: </strong>Sofpironium topical gel, 12.45%, applied topically once daily before bedtime is effective and well-tolerated for treatment of primary axillary hyperhidrosis in patients ≥9 years old.</p>","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-05DOI: 10.1016/j.jaad.2025.02.088
Emma Hansen, Abraham M Korman, Kristopher Fisher, Catherine G Chung, Benjamin H Kaffenberger, Rachel M Kirven
{"title":"Patient risk factors and poor outcomes associated with multiple inpatient dermatology consultations in one year: A retrospective cohort study.","authors":"Emma Hansen, Abraham M Korman, Kristopher Fisher, Catherine G Chung, Benjamin H Kaffenberger, Rachel M Kirven","doi":"10.1016/j.jaad.2025.02.088","DOIUrl":"https://doi.org/10.1016/j.jaad.2025.02.088","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-04DOI: 10.1016/j.jaad.2025.02.084
Tejas P Joshi, Piya Malhan, Natalie Garcia, Ida F Orengo
{"title":"Melanoma-specific and overall survival in patients with single versus multiple primary melanoma: A national database study.","authors":"Tejas P Joshi, Piya Malhan, Natalie Garcia, Ida F Orengo","doi":"10.1016/j.jaad.2025.02.084","DOIUrl":"10.1016/j.jaad.2025.02.084","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-04DOI: 10.1016/j.jaad.2025.02.082
Caroline J Stone, Eliza Broadbent, Vikram N Sahni, Laurel Gray, Jennie T Clarke, Christopher B Hansen, Jamie L W Rhoads, John J Zone, Christopher M Hull, Yelena P Wu, Jacob Kean, Aaron M Secrest, Zachary H Hopkins
{"title":"Use of the Connor-Davidson Resilience Scale in a Complex Medical Dermatology Clinic: Cross-sectional study evaluating associations between resilience, Health-related Quality of Life and Mental Health.","authors":"Caroline J Stone, Eliza Broadbent, Vikram N Sahni, Laurel Gray, Jennie T Clarke, Christopher B Hansen, Jamie L W Rhoads, John J Zone, Christopher M Hull, Yelena P Wu, Jacob Kean, Aaron M Secrest, Zachary H Hopkins","doi":"10.1016/j.jaad.2025.02.082","DOIUrl":"https://doi.org/10.1016/j.jaad.2025.02.082","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号